In December 2005, Eli Lilly and Enterprise agreed to plead guilty and pay back $36 million in reference to the unlawful marketing with the drug.[264] Sales representatives have been experienced to market Evista for breast most cancers and cardiovascular disease, to prompt or bait concerns by doc